Literature DB >> 30191045

Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.

Amir A Rahnemai-Azar1,1, Pallavi Pandey2,2, Ihab Kamel3,3, Timothy M Pawlik4,4.   

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is one of the fatal gastrointestinal cancers with increasing incidence and mortality. Although surgery offers the only potential for cure in iCCA patients, the prognosis is not optimal with low overall survival rate and high disease recurrence. Hence, adjuvant therapy is generally recommended in the management of high-risk patients. Identifying factors associated with disease recurrence and survival of the iCCA patients after resection will improve understanding of disease prognosis and help in selecting patients who will benefit from surgical resection or stratifying them for clinical trials. Despite development of new methods for early detection of tumor recurrence, effective prognostic models and nomograms, and recent advances in management, significant challenges remain in improving the prognosis of iCCA patients.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; liver cancer; outcome; prognosis; recurrence; surgical resection; survival; systemic therapy; tumor marker

Year:  2017        PMID: 30191045      PMCID: PMC6095314          DOI: 10.2217/hep-2016-0009

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  146 in total

1.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

Review 2.  Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.

Authors:  M Shimoda; D G Farmer; S D Colquhoun; M Rosove; R M Ghobrial; H Yersiz; P Chen; R W Busuttil
Journal:  Liver Transpl       Date:  2001-12       Impact factor: 5.799

3.  Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.

Authors:  Sung Yong Oh; Chi Young Jeong; Soon Chan Hong; Tae Hyo Kim; Chang Yoon Ha; Hyun Jin Kim; Gyeong-Won Lee; In Gyu Hwang; Joung Soon Jang; Hyuk-Chan Kwon; Jung Hun Kang
Journal:  Invest New Drugs       Date:  2010-04-01       Impact factor: 3.850

4.  The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases.

Authors:  M D'Angelica; Y Fong; S Weber; M Gonen; R P DeMatteo; K Conlon; L H Blumgart; W R Jarnagin
Journal:  Ann Surg Oncol       Date:  2003-03       Impact factor: 5.344

5.  Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations.

Authors:  Dushyant V Sahani; Sanjeeva P Kalva; Leena M Hamberg; Peter F Hahn; Christopher G Willett; Sanjay Saini; Peter R Mueller; Ting-Yim Lee
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

6.  [A case of curatively resected advanced intrahepatic cholangiocellular carcinoma through effective response to neoadjuvant chemotherapy].

Authors:  Kazuhiko Hashimoto; Takeshi Tono; Kentaro Nishida; Ryouji Nonaka; Ryou Tsunashima; Yujiro Fujie; Shoichiro Fujita; Junya Fujita; Tetsuya Yoshida; Tadashi Ohnishi; Shingi Imaoka; Takushi Monden
Journal:  Gan To Kagaku Ryoho       Date:  2014-11

7.  Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.

Authors:  Gianpaolo Carrafiello; Domenico Laganà; Elisa Cotta; Monica Mangini; Federico Fontana; Francesca Bandiera; Carlo Fugazzola
Journal:  Cardiovasc Intervent Radiol       Date:  2010-04-22       Impact factor: 2.740

Review 8.  Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma.

Authors:  Lucas M Boehm; Thejus T Jayakrishnan; John T Miura; Anthony J Zacharias; Fabian M Johnston; Kiran K Turaga; T Clark Gamblin
Journal:  J Surg Oncol       Date:  2014-09-01       Impact factor: 3.454

9.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

10.  Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival.

Authors:  Peti Thuwajit; Watinee Chawengrattanachot; Chanitra Thuwajit; Banchob Sripa; Anucha Paupairoj; Siri Chau-In
Journal:  J Gastroenterol Hepatol       Date:  2008-05       Impact factor: 4.029

View more
  2 in total

1.  Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma.

Authors:  Jun Li; Jiongjiong Lu; Shaodong Lv; Xinjun Wang; Xingyang Zhong; Junhua Lu; Shujun Sun; Caifeng Liu; Feng Xu; Haiying Sun; Jiamei Yang
Journal:  BMC Gastroenterol       Date:  2022-05-30       Impact factor: 2.847

2.  High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma.

Authors:  Xiaolong Du; Chen Zhang; Chuanzheng Yin; Wenjie Wang; Xueke Yan; Dawei Xie; Xichuan Zheng; Qichang Zheng; Min Li; Zifang Song
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.